KYUNG DONG

I.R.

Company credited for technology, KyungDong Pharm

Consolidated Statement of Financial Positio
Category	2024	2023	2022
Current Assets	101,829,283,957	89,748,780,615	102,981,141,677
Non-Current Assets	201,043,341,666	203,221,984,570	207,496,766,677
Total Assets	302,872,625,623	292,970,765,185	310,477,908,354
Current Liabilities	78,428,372,667	59,027,091,132	50,126,818,428
Non-Current Liabilities	4,107,296,294	5,466,631,932	2,826,326,535
Total Liabilities	82,535,668,961	64,493,723,064	52,953,144,963
Issued Capital	15,684,383,000	15,684,383,000	15,684,383,000
Capital Surplus	34,100,089,969	34,108,284,559	34,108,284,559
Elements of Other Stockholder’s Equity	-30,296,776,552	-29,080,294,586	-29,080,294,586
Comprehensive Income/Loss Accumulated	7,273,682,687	8,850,369,760	4,691,902,583
Retained Earnings	193,299,376,887	198,616,236,105	231,799,656,027
Non-Controlling Interests	276,200,671	298,063,283	320,831,808
Total Equity	220,336,956,662	228,477,042,121	257,524,763,391

Consolidated Statement of Comprehensive Income
Category	2024	2012	2022
Sales	193,936,297,352	162,674,098,953	182,718,157,223
Cost of Sales	79,534,271,686	73,261,360,202	86,604,567,067
Gross Profit	114,402,025,666	89,412,738,751	96,113,590,156
Technology Development Expenses	8,652,183,217	10,778,881,532	11,042,410,730
Selling General Administrative Expenses	103,126,237,472	103,588,413,925	76,759,150,913
Operating Profit	2,623,604,977	-24,954,556,706	8,312,028,513
Profit (loss) Before Tax	5,221,072,176	-18,503,488,246	17,941,194,955
Income Tax Expense	-226,717,114	2,226,835,306	5,828,423,200
Profit (Loss)	5,447,789,290	-20,730,323,552	12,112,771,755